• Minoryx
    Minoryx
    Home
    Our Company
    Who we areManagement teamBoard of directorsScientific advisory boardFunding
    Our Science
    OverviewAdrenoleukodystrophyFriedreich's ataxia
    Our Programs
    OverviewLeriglitazone
    Clinical Studies
    Clinical Studies ADVANCEFRAMESNEXUSResourcesExpanded Access Policy
    Media
    Careers
    Follow us
    Contact
    Clinical Studies
    Home Clinical Studies
  • The ADVANCE Clinical Study in AMN

    The ADVANCE trial is a pivotal phase 2/3 randomized, double-blind, placebo-controlled, clinical study with an open-label extension that has been designed to assess the efficacy and safety of leriglitazone in male patients with adrenomyeloneuropathy (AMN).

    More info
    The FRAMES Clinical Study in FRDA

    The FRAMES trial is a phase 2 randomized, double-blind, placebo-controlled, clinical study that has been designed to assess the efficacy and safety of leriglitazone in patients with Friedreich's ataxia (FRDA). This study has been designed with input from EU and US clinical experts and patient advocacy groups.

    More info
    The NEXUS Clinical Study in cALD

    The NEXUS clinical trial is a phase 2, open-label clinical study that has been designed to assess the efficacy and safety of leriglitazone in male pediatric patients with early stage cerebral X-linked adrenoleukodystrophy (cALD).

    See more
  • Contact

    Feel free to contact us in case you are interested in any of our clinical studies or programs.

    info@minoryx.com
    +34 93 544 14 66
  • Contact
    Headquarters
    https://www.minoryx.com/content/imgs/mail/logo.png
    Av. Ernest Lluch 32
    08302 MatarĂ³
    (Barcelona) Spain
    info@minoryx.com 0034935441466+34 93 544 14 66
    Belgian R&D Site
    https://www.minoryx.com/content/imgs/mail/logo.png
    Ave. Jean Mermoz 32
    6041 Gosselies
    (Charleroi) Belgium
    info@minoryx.com 0032023420803+32 (0)2 342 08 03
    Contact
    Follow us
    Legal Notice Privacy Policy Cookies Policy
    by eMascarĂ³